

## BSc Sem.-4 Examination

CC 205

Health &amp; Hygiene

May 2022

Time : 2-00 Hours]

Max. Marks : 50

- |  |   |
|--|---|
| 1. (A) Write down on Drug development and clinical trials.                                 | 7 |
| (B) Explain response variables and biomarkers.   | 7 |
| 2. (A) Discuss planning and design of clinical study.                                      | 7 |
| (B) Write brief detail note on concept of Bioavailability and Bioequivalence.              | 7 |
| 3. (A) Explain tools and software use in clinical studies.                                 | 7 |
| (B) Give detail on delays and conflicts of interest.                                       | 7 |
| 4. (A) Discuss clinical data management and biostatics.                                    | 7 |
| (B) Discuss the guidance for reporting and publication bias in clinical report.            | 7 |
| 5. (A) Give details note on regulation in clinical research.                               | 7 |
| (B) Discuss politics of research on women and religion.                                    | 7 |
| 6. (A) Discuss the current regulatory requirements and over view for new drug application. | 7 |
| (B) Explain regulation of agency for drug approval in India.                               | 7 |
| 7. (A) Explain the Belmont report.   | 7 |
| (B) Explain investigational new drugs regulation.  | 7 |
| 8. (A) Discuss drug accountability.  | 7 |
| (B) Write down any two-case study on clinical research.                                    | 7 |
| 9. Answer the following (Any eight)  | 8 |
| 1. Define: Biomarkers.   |   |
| 2. Function of clinical trials.  |   |
| 3. What is PK/PD modeling.   |   |
| 4. Define: Baseline issues.  |   |
| 5. Full form of NDA.   |   |
| 6. Function of FDA.  |   |
| 7. Define: BLAST.  |   |
| 8. Explain Thrombosis.   |   |
| 9. What is Risk identification?  |   |
| 10. Define suppression.  |   |
| 11. Planning of clinical study.  |   |
| 12. Two agency name of drug approval in Gujarat.   |   |